Home
Chemicals

Sector: Chemicals

Early patent licensing strategy, investment helped GE Licensing revolutionise LED displays

As its PFS licensing programme turns 10, GE’s IP executives reflect on lessons learned in cracking a brand new market

Five things to know as cannabis innovation and patenting rockets

Almost 150% increase in US cannabis-infused edibles patenting since 2018, but top food and beverage companies are missing out

Covid impact on US patent filings is now becoming clearer

Data on law firms ranked by 2021 grants shows a slide that may link to filing strategies changing because of pandemic-induced budget cuts

Latest content

Samsung, LG and South Korea’s trade secrets dilemma

The long read: Few countries are more focused on the threat of IP leaks to China than South Korea. But when it comes to shoring up legal protections for trade secrets, senior leaders have put on the brakes, anticipating threats to key industry players and national technology goals

03 March 2021

Dialog’s patents will boost Renesas’ fast growing licensing business

The purchase of the UK chipmaker will contribute to the monetisation programme’s potential, particularly within circuit technologies

19 February 2021

Seven top IP tips for biotech SMEs

How smaller biotechs can best overcome pitfalls and maximise the value of their inventions

18 February 2021

Uptrend in oppositions could spell costly delays for Indian patent applicants

Practitioners say greater attention to detail during the prosecution process can head off frivolous challenges

15 February 2021

Ford CEO weighs in on “really embarrassing” South Korean battery trade secrets fight

With the auto giant set for a high-profile roll out of several new electric vehicles, the dispute between LG Chem and SK Innovation is once again in the spotlight

12 February 2021

How the rise of PTAB discretionary denials impacts Hatch-Waxman strategies

The recent rejection of a Mylan IPR petition – currently being challenged at the Federal Circuit – is good news for pharma patentees and bad news for generics

11 February 2021

SCOTUS’ denial of certiorari in Idenix v Gilead poses especially difficult IP questions for universities and small biotechs

Recent caselaw has raised serious doubts over the enforceability of US genus claims, leaving life sciences innovators in a quandary

04 February 2021

Unlock unlimited access to all IAM content